VOSOL
LOE ApproachingNDAOTICSOLUTION/DROPS
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSOL is an otic solution approved in 1960 for treatment of ear conditions, administered as drops directly into the ear canal. The exact mechanism of action and pharmacologic class are not publicly detailed, but otic solutions of this era typically treat infections, inflammation, or cerumen impaction. This is a legacy small-molecule formulation with long clinical validation.
LOE Approaching
LOE is approaching for this 60+ year old product, signaling that brand teams are likely focused on defending market share and managing transition planning rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal that VOSOL is a maintenance-mode product with minimal new hiring. Career opportunities are limited to backfill or existing role transitions, making this a stabilizing rather than growth assignment.
Brand ManagerProduct Manager
Worked on VOSOL at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.